Gene-expression Profiling in Patients with Plasma Cell Myeloma Treated with Novel Agents.
نویسندگان
چکیده
BACKGROUND/AIM Novel agents such as thalidomide, lenalidomide and bortezomib have in part anti-angiogenic properties. In this study, we examined gene expression of angiogenic molecules in patients with plasma cell myeloma (PCM). MATERIALS AND METHODS We included 93 patients with PCM treated with novel agents (immunomodulatory drugs (IMiDs), bortezomib or a combination of both). The mRNA levels of angiogenic molecules were measured using the Human Angiogenesis RT2 Profiler PCR Array. The response evaluation was performed after three cycles. RESULTS Regarding all 93 patients, gene expression of 15 out of 84 genes tested (pre- and post-treatment and changes in levels pre-treatment/post-treatment) were significantly different in responders compared to non-responders. Responders had a lower expression of pro-angiogenic factors and increased expression of antiangiogenic factors. CONCLUSION In the IMiD-treated groups we found significant changes of expression of angiogenic genes in responders compared to non-responders, whereas in the bortezomib-based group the difference in expression of angiogenic genes was not significant.
منابع مشابه
The effect of human amniotic fluid on the survival and proliferation of human myeloma cell lines RPMI8226 and U266 in comparison with the fetal bovine serum
Background: Multiple Myeloma is a Plasma Cell Malignancy. Since the study of pathogenicity mechanisms and messenger pathways involved in the causative agent cells is important in the laboratory environment and close to the physiological environment of the body, therefore, the best environment for the study of cells in the laboratory environment, an environment most closely resembling the physio...
متن کاملApoptotic effect of apoptin gene transduction on multiple myeloma cell line
Introduction: Following the first description of multiple myeloma (MM), as the second most prevalent hematologic malignancy, multiple promising advances have paved the way to increase the long-lasting complete remission for patients. In the era of the novel therapeutic approaches, the cloning of the apoptosis-inducing genes into the genome of malignant cells has attracted tremendous attention. ...
متن کاملCirculating miR-92a, miR-143 and miR-342 in Plasma are Novel Potential Biomarkers for Acute Myeloid Leukemia
MicroRNAs (miRNAs) are small non-coding RNAs that function as post-transcriptional gene expression regulators. The expression profiling of miRNAs has already entered into cancer clinics as diagnostic and prognostic biomarkers to assess tumor initiation, progression and response to treatment in cancer patients. Recent Studies opened the way for the use of circulating miRNAs as non-invasive diagn...
متن کاملCD93 is Selectively Expressed on Human Myeloma Cells but Not on B Lymphocytes
Background: CD93 has originally been known as a C1q receptor, and many studies have demonstrated that CD93 is expressed on hematopoietic stem cells, B cell progenitors, myeloid and monocytic cells. Moreover, CD93 is shown to be expressed on long-lived plasma cells, and CD93 deficient-mice display an impairment in plasma cell development. Objective: To investiga...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3
Gene expression profiling (GEP) of purified plasma cells 48 hours after thalidomide and dexamethasone test doses showed these agents’ mechanisms of action and provided prognostic information for untreated myeloma patients on Total Therapy 2 (TT2). Bortezomib was added in Total Therapy 3 (TT3), and 48 hours after bortezomib GEP analysis identified 80 highly survival-discriminatory genes in a tra...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Cancer genomics & proteomics
دوره 13 4 شماره
صفحات -
تاریخ انتشار 2016